Novavax appoints Dr. Robert Walker as EVP and Head of R&D to lead vaccine innovation and partnerships.

Novavax has appointed Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development. With over 30 years in drug and vaccine development, Dr. Walker will focus on advancing Novavax's R&D efforts, including Matrix adjuvant innovation and pipeline development. He succeeds Dr. Ruxandra Draghia-Akli and will report to CEO John C. Jacobs. This leadership change aims to strengthen Novavax's scientific progress and strategic partnerships to tackle global health challenges.